Advancing mRNA Medicines to Fight and Prevent Disease

At Moderna, we are driven by our mission to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients. We are currently advancing mRNA medicines to address serious unmet needs across several therapeutic areas and multiple diseases. Clinical (human) trials are now underway for several of our investigational mRNA vaccines and therapeutics.

Below is a list of clinical trials for which Moderna is actively recruiting participants. We have provided links to the study listings on www.clinicaltrials.gov, where you can find more information, including details on eligibility criteria and clinical trial locations.

If you are seeking additional information, please email clinicaltrials@modernatx.com.

Actively Recruiting Clinical Studies
 

Infectious Disease Studies



Disease Program Study Phase Study Focus More Info
Chikungunya virus  

mRNA-1388
Prophylactic Vaccine

Phase 1 Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects clinicaltrials.gov
Zika virus

mRNA-1325
Prophylactic Vaccine

Phase 1

Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

clinicaltrials.gov

 

Cancer Studies



Disease Program Study Phase Study Focus More Info
Solid tumors  

mRNA-4157
Personalized Cancer Vaccine

Phase 1 Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors (KEYNOTE-603) clinicaltrials.gov
Advanced / metastatic
solid tumors
or lymphoma

mRNA-2416
Intratumoral Immuno-Oncology
Therapeutic

Phase 1

Dose Escalation Study of mRNA 2416 for Intratumoral Injection to Patients with Advanced Malignancies

clinicaltrials.gov